Short Bowel Syndrome Therapeutics Market to Reach USD 5.2 Billion by 2032

Madhulika Kokate December 10, 2025

13 min read

The global Short Bowel Syndrome Therapeutics market is witnessing significant growth, driven by increasing cases of short bowel syndrome (SBS) and advancements in treatment options. Short bowel syndrome, a condition where patients suffer from malabsorption due to the surgical removal of a large portion of the small intestine, often results in severe nutritional deficiencies, dehydration, and diarrhea. As awareness about the condition rises and treatment options improve, the market for SBS therapeutics is expected to expand rapidly over the next decade.

Get Sample Report of Short Bowel Syndrome Therapeutics Market @ https://marketintelo.com/request-sample/45562

Market Overview

The global short bowel syndrome therapeutics market was valued at USD 2.3 billion in 2023 and is expected to reach USD 5.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.2% during the forecast period. This growth is driven by the increasing prevalence of SBS, improvements in medical technology, and the introduction of novel therapies. As the global population ages and the rate of complex surgeries involving small intestine removal rises, the demand for effective therapeutic solutions is expected to grow significantly.

Get Sample Report of Short Bowel Syndrome Therapeutics Market @ https://marketintelo.com/request-sample/45562

Key Market Drivers

Rising Incidence of Short Bowel Syndrome

The increasing number of SBS cases is one of the primary drivers of the market. Factors such as trauma, Crohn’s disease, and ischemia, which can lead to the surgical removal of parts of the small intestine, are becoming more common. As more individuals are diagnosed with SBS, the need for effective therapeutics, including parenteral nutrition (PN), enteral nutrition (EN), and pharmaceutical treatments, is rising. Additionally, improvements in surgical techniques are allowing patients to survive longer, increasing the demand for long-term SBS management options.

Advances in Therapeutic Treatments

There has been significant progress in the development of therapeutics aimed at managing SBS. While parenteral nutrition remains a key treatment, novel therapies such as GLP-2 (glucagon-like peptide 2) analogs, including teduglutide, are showing promising results. These medications promote intestinal growth and enhance nutrient absorption, offering patients improved quality of life. As more therapies are approved, the range of treatment options for SBS is expanding, and the market is expected to grow as a result.

Increased Awareness and Diagnosis

Rising awareness about SBS among healthcare professionals and patients has also contributed to market growth. Earlier diagnosis and better understanding of the condition have led to more effective treatment strategies. With advances in diagnostic technologies and the availability of more specialized care, the early intervention rate has increased, making it possible to manage SBS more efficiently and reduce complications.

Market Segmentation

By Type of Treatment

The short bowel syndrome therapeutics market can be segmented based on the type of treatment used, including medical therapies, parenteral nutrition, and enteral nutrition. Parenteral nutrition (PN) is still widely used for patients with severe malabsorption, as it bypasses the digestive tract and provides nutrients directly into the bloodstream. However, the increasing use of novel pharmaceutical therapies, such as GLP-2 analogs, is expected to drive the growth of the medical therapeutics segment, offering patients a more long-term, less invasive solution.

By Application

The market can also be segmented by application, such as hospital care, home healthcare, and outpatient care. The hospital care segment holds the largest share of the market due to the need for specialized care and monitoring of SBS patients. However, the home healthcare segment is expected to grow rapidly as patients with SBS increasingly manage their condition at home with the help of home infusion therapy and other treatment options.

By Region

Geographically, North America dominates the short bowel syndrome therapeutics market due to the high prevalence of SBS, advances in healthcare infrastructure, and the presence of leading pharmaceutical companies. Europe also holds a significant share of the market, supported by rising awareness and improving healthcare systems. The Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by improving healthcare access, rising disposable income, and increased adoption of advanced therapeutics.

Get Sample Report of Short Bowel Syndrome Therapeutics Market @ https://marketintelo.com/request-sample/45562

Market Challenges

High Treatment Costs

One of the key challenges in the short bowel syndrome therapeutics market is the high cost of treatment. Parenteral nutrition, in particular, can be expensive, requiring specialized equipment, frequent hospital visits, and long-term management. Furthermore, the cost of novel therapies like teduglutide can be prohibitive for some patients, creating a barrier to widespread adoption. While these therapies offer significant benefits, the price remains a challenge for both patients and healthcare systems, especially in lower-income countries.

Limited Access to Healthcare in Developing Regions

In many parts of the world, access to healthcare services remains limited, which hampers the ability to diagnose and treat SBS effectively. This lack of access to modern healthcare facilities and therapies, particularly in rural and underserved areas, poses a significant challenge to market growth. As a result, the full potential of the SBS therapeutics market is yet to be realized in many developing regions.

Read Full Research Study: https://marketintelo.com/report/short-bowel-syndrome-therapeutics-market

Market Opportunities

Technological Advancements in Drug Delivery Systems

Technological advancements in drug delivery systems present significant opportunities for the short bowel syndrome therapeutics market. The development of more effective and efficient delivery methods, such as subcutaneous injections, oral formulations, and sustained-release systems, is expected to enhance patient compliance and improve treatment outcomes. These innovations are poised to drive growth in the medical therapeutics segment, making long-term management of SBS more feasible for patients.

Expansion of Home Healthcare Solutions

The expansion of home healthcare solutions is another key opportunity in the SBS therapeutics market. As patients with SBS increasingly seek treatment options that allow them to manage their condition at home, the market for home-based therapies, including at-home parenteral nutrition, infusion pumps, and oral medications, is expected to grow. Advances in telemedicine and remote monitoring technologies are also enabling patients to receive personalized care from home, improving convenience and reducing hospital visits.

Research and Development of Novel Therapies

Ongoing research and development (R&D) in the area of SBS therapeutics is driving innovation and presenting new opportunities. The development of new pharmaceutical therapies that promote intestinal regeneration and enhance nutrient absorption holds great promise. As biotech and pharmaceutical companies continue to invest in R&D, the market is likely to see the introduction of groundbreaking treatments that address unmet medical needs and improve patient outcomes.

Conclusion

In conclusion, the short bowel syndrome therapeutics market is poised for substantial growth, driven by an increasing prevalence of SBS, advancements in therapeutic treatments, and rising awareness about the condition. With a projected CAGR of 9.2%, the market is expected to reach USD 5.2 billion by 2032. As novel therapies continue to emerge and healthcare access improves, the outlook for the SBS therapeutics market remains positive, offering significant opportunities for patients, healthcare providers, and industry stakeholders alike.

Related Report